Avastin Gets More Time for Review

October 2010
Pharmaceutical Representative;Oct2010, Vol. 40 Issue 10, p10
The article accounts on the report issued by the U.S. Food and Drug Administration regarding the extension of the review period for Avastin, a drug used to treat cancer including cancer of the breast, lungs, colon, brain, and kidneys.


Related Articles

  • Medicare to cover expensive cancer treatments.  // PharmacoEconomics & Outcomes News;7/16/2011, Issue 633, p11 

    The article reports on the plan of Medicare to cover Avastin bevacizumab for breast cancer treatment regardless of the decision of the U.S. Food and Drug Administration (FDA) to rescind Avastin approval for such indication in July 2011.

  • Most Doctors Back Avastin Withdrawal.  // Chain Drug Review;2/28/2011, Vol. 33 Issue 4, p93 

    The article reports on the support of fifty-eight percent of physicians in a poll by Sermo, on the move of the Food and Drug Administration (FDA) to pull the breast cancer indication for Avastin from the market.

  • Bevacizumab in Metastatic Breast Cancer: Ready for Prime Time? Mandock, Katherine; Soefje, Scott A.; Adams, R. // Journal of Hematology Oncology Pharmacy;Dec2011, Vol. 1 Issue 4, p6 

    The article focuses on the U.S. Food and Drug Administration's (FDA) decision to remove bevacizumab's current labeled indication for metastatic breast cancer (MBC). Postapproval trials required with the FDA approval for bevacizumab for treatment did not demonstrate an overall survival (OS)...

  • Fighting Fire with Fire: Rekindling the Bevacizumab Debate. Montero, Alberto J.; Vogel, Charles // New England Journal of Medicine;1/26/2012, Vol. 366 Issue 4, p374 

    The article discusses the controversy concerning the decision of the U.S. Food and Drug Administration (FDA) to revoke bevacizumab approval in 2012. It says that the agency opposed the use of the substance when combined with paclitaxel to treat patients with metastatic breast cancer. According...

  • Advisory Panel Rejects Avastin for Breast Cancer Treatment. Koroneos, George // Pharmaceutical Executive;Aug2010, Vol. 30 Issue 8, p13 

    The article reports on the decision of the U.S. Food and Drug Administration to discontinue the use of Avastin or bevacizumab as a treatment for breast cancer due to reports on inefficacy.

  • The Pharmaceutical Medicine Year that Was. Fox, Anthony W. // Pharmaceutical Medicine - New Zealand;2008, Vol. 22 Issue 6, p341 

    The author recalls various issues related to drug safety in the U.S. which transpired in 2008. The Food and Drug Administration (FDA) has received a 9% increase in funding at $1.73 billion, 39% and 13.5% of which went to the Centers for Drug and Biologics Evaluation and Research (CDER and CBER),...

  • Eye Infections Linked to Off-Label Avastin Use.  // BioWorld Today;9/6/2011, Vol. 22 Issue 172, p4 

    The article reports on an alert issued by the U.S. Food and Drug Administration (FDA) warning health care professionals that repackaged intravitreal injections of Avastin caused a cluster of serious eye infections in the Miami area.

  • FDA panel votes to pull Avastin in breast cancer, again. Ratner, Mark // Nature Biotechnology;Aug2011, Vol. 29 Issue 8, p676 

    The article focuses on an announcement by a panel of advisors of the U.S. Food and Drug Administration (FDA) that the cancer drug Avastin from Genentech is inefficient when used with chemotherapy as an initial treatment for breast cancer.

  • Adverse Reaction Research.  // Reactions Weekly;6/7/2008, Issue 1205, p5 

    The article reports on the preliminary results of a study which indicate an association between bevacizumab and diverticulitis in elderly patients. The researchers analyzed data from U.S. Food and Drug Administration (FDA) MedWatch adverse event reports and from a multicentre clinical trial of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics